The goal of this award mechanism is to accelerate the clinical introduction of medical products and technologies that target ovarian cancer biology. Near-term clinical impact is expected.
Proof-of-concept demonstrating the potential utility of the proposed product or a prototype/preliminary version of the proposed product should already be established; thus, preclinical studies in animals are not allowed.
Small-scale clinical trials (Phase 0, Phase 1, Pilot), studies enriching a clinical trial, and projects related to or associated with ongoing or completed clinical trials are allowed.
Relevant data, either published or unpublished, that support the study rationale are required.
Funding & Duration
The anticipated direct costs budgeted for the entire period of performance will not exceed US $600,000 (approx AUD $791,000).
The maximum period of performance is 3 years.
Independent investigator at or above the level of Assistant Professor (or equivalent) are eligible to submit applications.
Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply.
- Investigator-Initiated Research Award
- Ovarian Cancer Academy Award – Early Career Investigator
- Pilot Award
Submission Requirements & Due Dates
- 28 April 2016 – pre-proposal submitted via https://eBRAP.org.
- Copy of pre-proposal forwarded to the Research Branch ASAP.
- 27 July 2016 – full applications (by invitation only) submitted to the Research Branch for internal review.
- Grants Officer: Dr Don McMaster
- Email: email@example.com